Additionally, prolonged exposure to ADT or ARPis can induce AR mutations and gene amplification, thus promoting disease progression by increasing AR signaling and selecting for prostate cancer cells resistant to further treatment with these agents (5). The gene discussed is AR; the disease is prostate carcinoma.